Description
Ataxia-telangiectasia mutated (ATM) is a serine/threonine kinase that activates checkpoint signaling following double strand DNA breaks and genotoxic stress. Ku-60019 is a potent, reversible inhibitor of ATM kinase (IC
50 = 6.3 nM), blocking the phosphorylation of ATM substrate proteins. It is much less effective or without effect against a panel of 229 other kinases. Ku-60019 sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells
in vitro. It produces radiosensitization and increases survival
in vivo when administered intra-tumorally in orthotopic xenograft models of glioblastoma multiforme. Ku-60019 is particularly effective in producing lethality in cells with mutant p53 or that are deficient in PTEN.
Uses
KU-60019 is a potent and reversible inhibitor of ATM kinase, blocking the phosphorylation of ATM substrate proteins. It sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells in vitro.
in vivo
Despite PTEN-deficient control tumors reaching a 4-fold increase in size before PTEN wild-type controls, KU-60019-treated PTEN-deficient tumors display a statistically significant slowing in growth. This growth inhibition is especially evident at the start of the experiment (days 5-12) just after KU-60019 is administered (days 1-5)[2].
IC 50
ATM: 6.3 nM (IC
50); DNA-PKcs: 1.7 μM (IC
50)
References
[1] SARAH E GOLDING. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.[J]. Molecular Cancer Therapeutics, 2009: 2894-2902. DOI:
10.1158/1535-7163.mct-09-0519[2] SARAH E GOLDING. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.[J]. Cell Cycle, 2012, 11 6: 1167-1173. DOI:
10.4161/cc.11.6.19576[3] LAURA BIDDLESTONE-THORPE. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.[J]. Clinical Cancer Research, 2013, 19 12: 3189-3200. DOI:
10.1158/1078-0432.ccr-12-3408[4] NUALA MCCABE. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.[J]. Cancer research, 2015: 2159-2165. DOI:
10.1158/0008-5472.can-14-3502